Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

The objectives of this study were to characterize the pharmacokinetics (PK) of LY2510924, a potent peptide antagonist of the CXCR4 receptor, after subcutaneous administration in patients with advanced cancer forms and quantify LY2510924 stimulatory effects on the mobilization of cells bearing the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bihorel, S, Raddad, E, Fiedler‐Kelly, J, Stille, JR, Hing, J, Ludwig, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613202/
https://www.ncbi.nlm.nih.gov/pubmed/28643374
http://dx.doi.org/10.1002/psp4.12221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613202/
https://www.ncbi.nlm.nih.gov/pubmed/28643374
http://dx.doi.org/10.1002/psp4.12221

Ejemplares similares